Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases
- 30 August 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in Endocrine Research
- Vol. 47 (1), 18-25
- https://doi.org/10.1080/07435800.2021.1955255
Abstract
Glucagon-like peptide 1 receptor agonists (GLP1Ra) are commonly used in type 2 diabetes mellitus (T2DM). However, differential risk of various cancers among GLP1Ra recipients is unknown. We inquired an aggregated electronic health record database, Explorys, and compared the adjusted odds ratio (aOR) of cancers between GLP1Ra and metformin users. Findings were validated in the FDA Adverse Event Reporting System (FDA FAERS). From 1/2005 to 6/2019, we identified 619 340 and 64 230 patients in the metformin and GLP1Ra group, respectively. Within 5 years of starting antidiabetic medications, GLP1Ra was associated with significantly lower incident risk of prostate (aOR 0.81, p = .03), lung (aOR 0.81, p = .05), and colon cancer (aOR 0.85, p = .03), while the risk of thyroid cancer was significantly higher (aOR 1.65, p < .01). Similar findings were seen in the FDA FAERS database, where GLP1Ra was associated with lower risk of prostate (aOR 0.72, p = .08), lung (aOR 0.52, p < .01), colon cancer (aOR 0.82, p = .31), and higher risk of thyroid cancer (aOR 4.33, p < .01). In addition, with longer duration of GLP1Ra use, the risk of prostate, lung, and colon cancer further decreased, suggesting an exposure duration–response relationship. GLP1Ra is associated with lower risks of prostate, lung, and colon cancer, but higher risk of thyroid cancer.Keywords
This publication has 28 references indexed in Scilit:
- Glucagon-Like Peptide-1 (GLP-1) Reduces Mortality and Improves Lung Function in a Model of Experimental Obstructive Lung Disease in Female MiceEndocrinology, 2013
- GLP1 and cancer: friend or foe?Endocrine-Related Cancer, 2012
- Glucagon Like Peptide-1 Receptor Expression in the Human Thyroid GlandJournal of Clinical Endocrinology & Metabolism, 2012
- Incretin Receptors in Non-Neoplastic and Neoplastic Thyroid C Cells in Rodents and Humans: Relevance for Incretin-Based Diabetes TherapyNeuroendocrinology, 2011
- Glucagon-Like Peptide-1 Receptor Activation Inhibits Growth and Augments Apoptosis in Murine CT26 Colon Cancer CellsEndocrinology, 2011
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based TherapiesGastroenterology, 2011
- Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell ProliferationEndocrinology, 2010
- Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic TherapyThe New England Journal of Medicine, 2010
- GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo TargetingJournal of Nuclear Medicine, 2007
- Minireview: The Glucagon-Like PeptidesEndocrinology, 2001